{"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG000","lowerLimit":"4.2","upperLimit":"NA","value":"22.9"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG001","lowerLimit":"6.4","upperLimit":"NA","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by investigator assessment is presented. Per protocol, only data for Cohorts A and B were presented for this endpoint.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG000","title":"Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG001","title":"Cohort B: Ovarian Cancer (Lenva + Pembro)"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention and had confirmed complete response or partial response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Duration of Response (DOR) Per RECIST 1.1 by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}